Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03575390
Other study ID # B10601002-3
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 30, 2018
Est. completion date January 31, 2022

Study information

Verified date August 2023
Source Dalin Tzu Chi General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pomegranate has anti-oxidative capacity. It might reduce symptoms of Alzheimer's disease, Drug-induced hepatitis, and might prevent deterioration of cardiovascular diseases and cancer progression. But, the beneficial effects of pomegranate on hearing impairment was still unclear. This study aimed to investigate the beneficial effects of pomegranate on hearing impairment by a prospective, randomized, double-blinded clinical trial design. The investigators'll include 120 elderly patients without hemodialysis in our hospital, and divided them into 2 groups. Control group will receive placebo treatment; pomegranate group will receive oral pomegranate (500 mg, twice per day). All patients received the above treatment for 9 months, and underwent pure tone audiometry and word discrimination scores before the start of the clinical trial and at the end of the treatment (9th month).


Description:

Pomegranate has anti-oxidative capacity. It might reduce symptoms of Alzheimer's disease, Drug-induced hepatitis, and might prevent deterioration of cardiovascular diseases and cancer progression. But, the beneficial effects of pomegranate on hearing impairment was still unclear. This study aimed to investigate the beneficial effects of pomegranate on hearing impairment by a prospective, randomized, double-blinded clinical trial design. The investigators'll include 120 elderly patients without hemodialysis in our hospital, and divided them into 2 groups. Control group will receive placebo treatment; pomegranate group will receive oral pomegranate (500 mg, twice per day). All patients received the above treatment for 9 months, and underwent pure tone audiometry and word discrimination scores before the start of the clinical trial and at the end of the treatment (9th month). Age-related hearing impairment (ARHI) was very common in the elderly. Hearing deteriorated not only due to problems with the peripheral hearing organs, but also because of degeneration of the central auditory system. In general, peripheral hearing deteriorates more quickly and severely in male subjects than in female subjects, more severely at higher than low frequencies, and more quickly in the central auditory system than the peripheral hearing organs. 1. Mechanisms of ARHI: In addition to genetic susceptibility, environmental factors, including obesity, obstructive sleep apnea, systemic diseases, noise, chemical exposure, alcohol, tobacco, ototoxic medication, diet, hormonal factors, menopause and socioeconomic status, may also contribute to hearing degeneration. Contributing mechanisms of this disease may include hypoxia/ischemia, reactive species formation, oxidative stress, and apoptotic/necrotic death of inner ear hair cells/spiral ganglion cells, neural cells, or vascular endothelial cells. Poor serum vitamin B-12 and folate status levels may be associated with age-related auditory dysfunction in older females. Elevated plasma methylmalonic acid (MMA) concentration may be associated with hearing loss in older adults. Hearing function of noise-exposed workers was negatively correlated with plasma vitamin E levels. But, one report reported that plasma levels of homocysteine, erythrocyte folate and vitamin B6 were not associated with severity of age-related hearing impairment. Serum magnesium and vitamin C levels were also not correlated with severity of noise-induced hearing loss. The glutathione peroxidase (GPx) 6 gene was upregulated while the thioredoxin reductase 1 gene was downregulated in mice with ARHI. Furthermore, our study group had found that plasma reactive oxygen species levels were correlated with severity of ARHI in humans. 2. Prevention and/or treatment of ARHI It is reasonable to expect that improved endogenous antioxidant capacity and/or exogenous antioxidant supplementation may suppress oxidative damage to the cells of auditory system. Some agents were reported to be beneficial for the senescent auditory system. For example, (-)-Epigallocatechin-3-gallate(EGCG) could protect cultured spiral ganglion cells from hydrogen peroxide-induced oxidizing damage. Vitamin C or E could prevent ARHI in animals. Coffee and caffeine were good for auditory neuropathy of mice. Also, antioxidants were also beneficial for the senescent auditory cortex of aged rats. B12 supplementation could prevent hearing loss in B12-deficient individuals. Folic acid supplementation slowed hearing decline slightly in low frequencies, but not in high frequencies in a population without folic acid fortification of food. Higher folate intake had lower risk of developing hearing loss in older males. Coenzyme Q10 (CoQ10) could slow down the deterioration of presbycusis. There was an inverse association between higher intakes of long-chain n23 poly-unsaturated fatty acid (PUFAs) and regular weekly consumption of fish and age-related hearing loss. Patients who achieved the highest plasma concentrations of vitamin C, vitamin E and selenium had significantly less loss of high-tone hearing. And, salicylate use and moderate alcohol intake were possible protective factors for ARHI. But, report claimed that life style with higher intake of vitamin C, E, beta carotene, or B12 did not reduce the risk of hearing loss in adult males. Vitamin E or atorvastatin cannot slow down the deterioration of presbycusis. Low-dose difluoromethylornithine (DFMO) could not protect hearing. 3. Introduction of pomegranate: Pomegranate is a subtropical and tropical fruit of great importance from a health point of view. It has antioxidant activity and antimutagenic potential. Oxidative and histologic evaluation showed that pomegranate juice might have a preventive effect in paracetamol-induced acute liver damage. Six weeks supplementation of pomegranate juice could have favorable effects on oxidative stress in patients with type 2 diabetes. Pomegranate extract alleviates disease activity and some blood biomarkers of inflammation and oxidative stress in rheumatoid arthritis patients. Pomegranate seed extract exhibited therapeutic potential for memory and muscular coordination in rats, which was most likely related at least in some part to its antioxidative and free radical scavenging actions. Long-term dietary supplementation with pomegranates from Oman attenuates cognitive and behavioral deficits in a transgenic mice model of Alzheimer's disease. Consumption of pomegranates improves synaptic function in a transgenic mice model of Alzheimer's disease. Pomegranate's neuroprotective effects against Alzheimer's disease are mediated by urolithin, its ellagitannin-gut microbial derived metabolites. A systematic review and meta-analysis of randomized controlled trials (RCTs) did not suggest any effect of pomegranate consumption on lipid profile and on plasma c-reactive protein levels. One report also concluded that the quality of previous studies about the use of dietary pomegranate preparations in the prevention and treatment of cardiovascular diseases was poor. Even in the best studies, indications of benefit did not reach the conventional levels of statistical significance. And, future studies need to prove the clinical benefit. Methanol extract of pericarp of pomegranate (PME) had anti-proliferative effect on human breast (MCF-7, MDA-MB-231), endometrial (HEC-1A), cervical (SiHa, HeLa), and ovarian (SKOV3) cancer cell lines, and normal breast fibroblasts (MCF-10A). Also, PME could modulate osteoblastic cell differentiation. Pomegranate evokes antiproliferative, anti-invasive, and antimetastatic effects, induces apoptosis through the modulation of Bcl-2 proteins, upregulates p21 and p27, and downregulates cyclin-cdk network. Furthermore, pomegranate blocks the activation of inflammatory pathways including, but not limited to, the nuclear factor kappa-light-chain-enhancer of activated B cells(NF-κB) pathway. However, another meta-analysis showed that the evidence of clinical effectiveness for cancer treatment in humans was poor because the quality of the studies was poor. 4. Pomegranate: A new candidate for ARHI treatment? Pomegranate has antioxidative capacity and could prevent Alzheimer's disease. Meanwhile, oxidative damage was one of the underlying mechanisms for ARHI. So, it is reasonable to expect that pomegranate might have a beneficial effect for ARHI.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date January 31, 2022
Est. primary completion date January 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 80 Years
Eligibility Inclusion Criteria: 1. Age 50 to 80 years old. 2. non-renal dialysis patients. Exclusion Criteria: 1. Life can not take care of themselves or the bed of a patient. 2. dialysis patients. 3. Patients who can not understand the details of this study or are unable to cooperate with the examination. 4. history of alcohol or drug abuse. 5. history of high environmental noise exposure. 6. The pure tone hearing threshold is greater than 10 decibel (dB), and the audiogram 4 kilohertz (kHz) air conduction threshold is greater than 8 kilohertz (kHz) air threshold value of 20 decibel (dB).

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Placebo
The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
Pomegranate
Pomegranate extract 500mg

Locations

Country Name City State
Taiwan Dalin Tzu Chi Hospital Chiayi City

Sponsors (1)

Lead Sponsor Collaborator
Dalin Tzu Chi General Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pure tone audiometry (PTA) pure tone thresholds of 250, 500, 1000, 2000, 4000, 8000 Hz were measured. 9 months
Secondary speech reception threshold (SRT) The speech recognition threshold is the lowest hearing level at which speech can barely be recognized or understood. The SRT is defined as the lowest hearing level at which the patient correctly repeats 50% of a list of spondaic words. Examples are airplane, hot dog, outside, ice cream, and baseball. Usually a very soft level (db HL). 9 months
Secondary speech discrimination score (SDS) The SDS test tool is a single syllable word list. Each table consists of 50 words, such as, look, go. The test method is to listen to the subject at a volume higher than the SRT value of 20 to 40 dB (30 dB), so that the subject repeats the spoken word sound. Based on the percentage of correct answers, normal people can repeat 95 to 100% of the words, and 80% or less of them are bad discriminating power and affect the understanding of language. SDS is usually expressed in %. 9 months
See also
  Status Clinical Trial Phase
Withdrawn NCT04055987 - Use of Electropalatography to Improve Speech Sound Production N/A
Completed NCT03687801 - Clinically Implementing Online Hearing Support Within Hearing Organization N/A
Enrolling by invitation NCT06051968 - Effects of an Online Hearing Support for First-time Hearing Aid Users N/A
Recruiting NCT05083221 - Effect of an Aural Rehabilitation Program in Hearing-impaired Older Adults N/A
Completed NCT04794179 - CROS and Quality of Life of Elderly Cochlear Implant Recipients and Their Care Givers N/A
Recruiting NCT05003674 - A Feasibility Study Evaluating the Performance of Focused Multipolar Stimulation in Adult Cochlear Implant Recipients N/A
Completed NCT01400178 - Cochlear Implants in Post-lingually Children: Results After 10 Years N/A
Completed NCT00738244 - Effectiveness of Hearing-aid Based Wind-noise Algorithm N/A
Completed NCT03716544 - Efficacy of Amplification With Hearing Aids for Tinnitus Relief N/A
Recruiting NCT02779907 - Prevalence and Associations of Paediatric Chronic Suppurative Otitis Media and Hearing Impairment in Rural Malawi N/A
Completed NCT02832128 - Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire) Phase 2
Completed NCT01816087 - Performances of a Brief Assessment Tool for the Early Diagnosis of Geriatric Syndromes by Primary Care Physicians N/A
Completed NCT00582946 - Wide-Bandwidth Open Canal Hearing Aid For Better Multitalker Speech Understanding Phase 1
Recruiting NCT05847426 - Improving Early Intervention in Hearing Impaired Children Using Functional Near-Infrared Spectroscopy (fNIRS) N/A
Recruiting NCT05854719 - Eyes On Lips? Speechreading Skills and Facial Expression Discrimination in Children With and Without Impaired Hearing N/A
Completed NCT04469946 - Hearing Aid Noise Reduction in Pediatric Users Pilot Study (Oticon Pilot Study) N/A
Withdrawn NCT03966144 - RoboHear™ Device: Advanced Haptic Technology That Allows the Deaf to Understand Speech N/A
Completed NCT02042404 - The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study N/A
Recruiting NCT05805384 - Evaluating a Noise Reduction Algorithm With Cochlear Implant Users N/A
Active, not recruiting NCT05815667 - Effects of the Swedish Internet-based Individualised Active Communication Education (I-ACE) in FTU N/A